Brodil® Levo is the preparation of Levosalbutamol. Levosalbutamol is a single isomer
ß2-agonist that differs from racemic salbutamol by elimination of (S)-salbutamol.
Levosalbutamol is an effective bronchodilator whose primary mechanism of action is
unimpeded by (S)-salbutamol. Thus when compared with racemic salbutamol,
clinically comparable bronchodilation can be achieved with doses that substantially
lessen beta-mediated side effects.
Indications and Uses
Brodil® Levo are indicated for the treatment of prevention or bronchospasm in
adults, adolescents, and children 6 years of age and older with reversible obstructive
Dosage and Administration
Brodil® Levo 1mg & 2 mg Tablets
Adults and adolescents above 12 years: 1-2 mg three times daily.
Brodil® Levo Syrup
Adults: 5-10 ml three times daily.
Children (6-11 Years): 5 ml three times daily.
Children (2-5 Years): 2.5 ml three times daily.
Brodil® Levo is contraindicated in patients with a history of hypersensitivity to any of
the components of the formulation.
Potentially serious hypokalemia may result from ß2-agonist therapy. Particular
caution is advised in acute severe asthma as this effect may be potentiated by
hypoxia and by concomitant treatment with xanthine derivatives, steroids and
diuretics. Serum potassium levels should be monitored in such situations.
Levosalbutamol should be used with caution in patients with cardiovascular
disorders, especially coronary insufficiency, cardiac arrhythmias or hypertension.
The most frequent side effects are palpitation, fine tremors of the skeletal muscle
(particularly the hand) and muscle cramps may occur. The other likely side effects
are gastrointestinal disturbances such as nausea, vomiting, burning substernal or
epigastric pain and diarrhoea. In some cases nervousness, headache, dizziness,
fatigue and sleeplessness may occur.
Pregnancy & Lactation
Use of oral levosalbutamol in pregnant or nursing mothers should be considered only
if the expected benefit to the mother is greater than any possible risk to the foetus
or the infant.
It is not known whether levosalbutamol is excreted in human milk. Caution should be
exercised when oral levosalbutamol is administered to a nursing woman.
Other short-acting sympathomimetic bronchodilators or epinephrine should be used
with caution with levosalbutamol. If additional adrenergic drugs are to be
administered by any route, they should be used with caution to avoid deleterious
Beta-blockers: Beta-adrenergic receptor blocking agents not only block the
pulmonary effect of beta-agonists such as levosalbutamol, but may also produce
severe bronchospasm in asthmatic patients.
Diuretics: Diuretics (such as loop or thiazide diuretics) can be acutely worsened
by beta-agonists. Hence, caution is advised in the coadministration of betaagonists
with non-potassium sparing diuretics.
Digoxin: Digoxin levels were demonstrated after single-dose intravenous and oral
administration of racemic salbutalmol, hence it is advisable to carefully evaluate the
serum digoxin levels in patients who are currently receiving digoxin and levosalbutamol.
Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: Levosalbutamol should be
administered with extreme caution to patients being treated with monoamine oxidase
inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such
agents, because the action of levosalbutamol on the vascular system may be
The expected symptoms with overdosge are tachycardia, nervousness, headache, tremor,
nausea, dizziness, fatigue and sleeplessness. Hypokalaemia also may occur. Treatment
consists of discontinuation of oral levosalbutamol together with appropriate symptomatic
therapy. In the event of serious poisoning, the stomach should be emptied and, if
necessary, a beta- blocker administered with caution in patients with a history of
Store in a cool & dry place. Protect from light & moisture.
Only logged in customers who have purchased this product may leave a review.